AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01076569 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04490746 — intervention group
Intervention type: OTHER
Intervention: with no intervention, Collect samples
Description: only with observation,there is no need to intervene
Study NCT02421614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-protein low-carbohydrate diet with high olive oil
Study NCT02421614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-protein low-carbohydrate diet with high sunflower oil
Study NCT03885895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q switched KTP (532nm)
Description: LASER
Study NCT01464593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyso-Thermosensitive Liposomal Doxorubicin
Description: Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
Study NCT01464593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% Dextrose Solution
Description: Single 30 minute intravenous infusion
Study NCT01464593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
Study NCT01631539 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DC Bead™
Description: chemoembolization with DC Bead™ loaded with Irinotecan
Study NCT01631539 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: 400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
Study NCT01631539 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5 FU
Description: every 2 weeks IV
Study NCT01631539 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: every 4 weeks chemoembolization
Study NCT03279822 — intervention group
Intervention type: OTHER
Intervention: not any intervention
Description: not any intervention
Study NCT02802787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camp Discovery
Description: Activities will include physical, social, emotional, sensory and spiritual activities.
Study NCT02596555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
Study NCT04110626 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires are completed at the 3 survey times (T0, T1 and T2) by all pupils involved. Collected data are quantitative
Study NCT04110626 — intervention group
Intervention type: OTHER
Intervention: Non-directive Interviews
Description: The interviews are conducted with 80 pupils/year randomly selected (i.e. 2 per class and 8 per establishment/year). Collected data are qualitative
Study NCT05109533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1
Description: Probiotics implementation
Study NCT04001725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.
Study NCT04001725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.
Study NCT04001725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
Study NCT01117038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil and enalapril
Description: enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
Study NCT01117038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil and amlodipine
Description: amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
Study NCT00981812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEM Breast Biopsy
Description: Breast biopsy using PEM guidance and Stereo Navigator software
Study NCT00917852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore Conformable TAG Thoracic Endoprosthesis
Description: Endovascular stent graft
Study NCT04301869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Oral versus intravenous therapy
Study NCT03783819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypericum perforatum oil
Description: Ointment containing Hypericum perforatum oil
Study NCT03783819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ointment containing plant oils used in Hypericum perforatum oil production and dye
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLS induced irritation
Description: 60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SLS induced irritation
Description: 60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tape-stripping
Description: Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tape-stripping
Description: Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UV radiation
Description: UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: UV radiation
Description: UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intact skin
Description: Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT03783819 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intact skin
Description: Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
Study NCT00375973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine po 60-120 mg/day for 12 weeks
Study NCT00375973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill dose comparable to duloxetine
Study NCT04459325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tigerase® and best available care
Description: Nebulised dornase alfa \[2.5 mg BID\] for 7 days
Study NCT04459325 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best available care
Description: Patients will receive the usual care in accordance with good practice.
Study NCT00786929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter drainage
Study NCT00786929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Study NCT02680054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Asp(B28)-
Description: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
Study NCT04514159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is the study drug.
Study NCT04514159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib (VERZENIO®) is an approved drug.
Study NCT04036175 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen
Description: Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2>= 92%
Study NCT00210418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified food rations
Description: The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ \<-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
Study NCT00210418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified food rations
Description: The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ \<-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
Study NCT00210418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and communication to improve feeding practices
Description: The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
Study NCT00210418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and communication to improve feeding practices
Description: The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
Study NCT04578457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR enabled
Description: Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
Study NCT04578457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(1)
Description: Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
Study NCT04578457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(2)
Description: Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
Study NCT04578457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(3)
Description: Each participant will be fitted with a third noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1) and NR(2).
Study NCT00502541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Repeat macular grid laser or observation
Study NCT06254118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fatty Acids
Description: 1000mg omega-3 fatty acids taken once daily with meals for 12 months
Study NCT06254118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: olive oil
Description: 1000mg olive oil taken once daily with meals for 12 months
Study NCT01339195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French adaptation of NINDS-Canadian Stroke Network battery
Description: * clinical: post-stroke neurological follow-up assessment~* neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~* MRI
Study NCT02129166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dasatinib
Description: In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
Study NCT02129166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib+Imatinib
Description: In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose
Study NCT04234490 — intervention group
Intervention type: PROCEDURE
Intervention: Parenteral nutrition
Description: Impact of parenteral nutrition on patient quality of life over time and impact on carer burden
Study NCT03532256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observation
Description: Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
Study NCT03963492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
Study NCT03963492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
Study NCT04595045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A infiltrations
Description: Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice
Study NCT03903991 — intervention group
Intervention type: OTHER
Intervention: Temperature recording
Description: Tympanic and oesophageal temperatures will be recorded during the procedure
Study NCT00294866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
Study NCT03532256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Text to online survey
Description: Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
Study NCT00294866 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Paricalcitol
Description: Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
Study NCT03823170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: The low-power, infrared (808nm wavelength) diode laser with a power of 100mW will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
Study NCT03823170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorotherapy
Description: The treatment will be carried out with the application of fluoride varnish, with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
Study NCT03532256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bi-directional text script
Description: Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
Study NCT04342403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life
Description: Quality of life instruments including King's Sarcoidosis Questionnaire (KSQ) and Sarcoidosis Assessment Tool (SAT)
Study NCT00350857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Carbamazepine
Study NCT02049359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Texting
Description: Bidirectional texting once weekly for 12 weeks
Study NCT03823170 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Laser therapy and Fluorotherapy
Description: This group will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
Study NCT01981707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-Choline-PET
Study NCT03097276 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blood sample will be collected
Study NCT03097276 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CT scan
Description: CT scan
Study NCT02407613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Sonalleve MR-HIFU Breast Tumor Therapy System
Description: Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
Study NCT01541761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family groups
Description: The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
Study NCT02227498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effect of Argus II on Functional Vision
Description: To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
Study NCT03512054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized 5-step weaning procedure
Description: Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver...) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation
Study NCT02049086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT-PM
Description: Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
Study NCT02049086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Module
Description: The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
Study NCT02753400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emixustat hydrochloride
Description: Tablet for oral administration
Study NCT02753400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets for oral administration contain only inactive ingredients
Study NCT02753400 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration contain only inactive ingredients
Study NCT00217412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT01164189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
Study NCT01164189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.